ClinicalTrials.gg
Not yet recruitingNCT06942182Updated Apr 24, 2025

Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

A Phase 2 interventional study of Isomyosamine 250mg and Placebo 250 mg in Sarcopenia in Elderly, Frailty and Frailty/Sarcopenia, sponsored by TNF Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by TNF Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.

02

Conditions studied

  • Sarcopenia in Elderly
  • Frailty
  • Frailty/Sarcopenia
  • Frailty in Older Adults

Keywords

  • sarcopenia
  • Frailty
  • Hip Fracture
  • Older population
  • Gerontological
  • Femur fracture
  • Sarcopenia and Frailty
03

In context

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 60 is below the median of 82 across 769 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

TNF Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 60 to 85 years of age
  2. Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall
  3. Concomitant medication limited to treatment for chronic conditions
  4. The ability to give and comply with study procedures
  5. Body weight ≥35 kg
  6. Adequate dietary intake
  7. Potential subjects' intention to avoid reproductive activity will be confirmed

    And one or more of the following criteria:

  8. Previous history frailty or sarcopenia diagnosis using standardized tests;
  9. Positive assessment for frailty or sarcopenia using standardized tests or as per clinician's judgement;
  10. Previous positive assessment for elevated biomarkers of inflammation (serum IL-6 level> LOQ, TNFR1 level > LOQ, and/or TNF-alpha level > LOQ)

Exclusion criteria

Exclusion Criteria:

  1. Receiving immunotherapy for cancer or solid organ transplantation
  2. Complex or comminuted fracture or fracture of multiple long bones
  3. Regular treatment for chronic disease including chronic renal failure, chronic heart failure (CHF) cerebrovascular disease including stroke, rheumatoid arthritis, or polymyalgia rheumatica
  4. Chronic kidney disease (estimated [eGFR] \<60 mL/min)
  5. Newly (\< 2 weeks) diagnosed COVID-19
  6. Inability or unwillingness to give written
  7. History of upper/lower respiratory tract infection, requiring systemic , antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit
  8. History of adverse reaction or allergy to TNF inhibitor
  9. History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion
  10. Currently under treatment by an anti-TNFα drug, such as adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and biosimilars
  11. Currently under treatment by an anti-diabetic medication, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide, or any of metformin, jenuvia, or insulin
  12. Unwillingness or inability to comply with study procedures, including smoking cessation
  13. History of epilepsy or seizure propensity, ataxia, abnormal EEG findings, abnormal brain magnetic resonance image, or other co-morbid neurological conditions
  14. Positive TB test
  15. Patients who are pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Study Drug: 1000 mg Isomyosamine

    Subjects randomly assigned to receive 1000 mg Isomyosamine daily via four 250 mg capsules

    Drug: Isomyosamine 250mg

  • Placebo comparator
    Placebo 1000 mg

    Subjects randomly assigned to receive 1000 mg placebo daily via four 250 mg capsules

    Drug: Placebo 250 mg

Interventions

  • DrugIsomyosamine 250mg

    Isomyosamine 250 mg capsules dosed 4 times daily

  • DrugPlacebo 250 mg

    Placebo 250 mg capsule 4 times daily

06

What researchers measure

Primary outcomes

  1. Change in Short Physical Performance Battery (SPPB) Test in subjects treated with Isomyosamine or placebo

    Time frame: From enrollment to the end of treatment at 90 days

Secondary outcomes

  1. 4-meter walk test

    Change in the time taken to walk 4 meters through 90 days dosing.

    Time frame: From enrollment to the end of treatment at 90 days

  2. 6-minute walk test

    Change in the distance walked in the 6-minute walk test (m) through 90 days dosing.

    Time frame: From enrollment to the end of treatment at 90 days

  3. Grip strength

    Change in grip strength score over 90 day dosing.

    Time frame: From enrollment to the end of treatment at 90 days

  4. Effect on serum levels of biochemical markers of TNF activation

    Time frame: From enrollment to the end of treatment at 90 days

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in the Isomyosamine vs Placebo groups

    Time frame: From enrollment to the end of treatment at 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Mar 2026, 10 months later.

Of 20 phase 2 interventional studies under Frailty, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 94. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 24, 2025
StartEst.
May 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942182
Lead sponsor
TNF Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Apr 24, 2025

Study contacts

Dan Mazzucco
Contact
dmazzucco@3-e-a.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion